IMPORTANCE Preclinical and human data suggest that hippocampal dysfunction plays a critical role in the onset of psychosis. Neural hyperactivity in the hippocampus is thought to drive an increase in subcortical dopamine function through glutamatergic projections to the striatum.
B oth preclinical and human studies suggest that hippocampal dysfunction plays a critical role in the onset of psychosis. Data from animal models indicate that neural hyperactivity in the hippocampus drives an increase in subcortical dopamine function through glutamatergic projections to the striatum.
1,2 Neuroimaging studies in individuals at clinical high risk for psychosis suggest that the subsequent onset of psychosis is associated with changes in several measures of hippocampal integrity, including hypermetabolism, 3 increased resting perfusion, 4 altered activation in response to cognitive tasks, 5 and reduced gray matter volume. 3, 6, 7 The mechanisms underlying these changes are unclear, but experimental work in rodents suggests that these changes may be secondary to increases in hippocampal glutamate levels.
3 A large body of independent research suggests that psychosis involves alterations in glutamate neurotransmission. 8, 9 For example, noncompetitive N-methyl-D-aspartate receptor antagonists such as ketamine hydrochloride and phencyclidine can induce psychotic symptoms in healthy individuals, 10, 11 and exacerbate psychotic symptoms in individuals with a psychotic disorder. 12, 13 In addition, autoantibodies to the N-methyl-D-aspartate receptor are present in a proportion of individuals with psychosis, 14, 15 and several risk genes associated with psychosis code for proteins involved in glutamatergic neurotransmission.
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Brain glutamate levels can be measured in vivo using proton magnetic resonance spectroscopy ( 1 H-MRS). A meta-analysis on levels in levels of glutamatergic metabolites in individuals with psychosis suggests that there are elevations of glutamatergic metabolites in several brain regions, including increased concentrations of Glx (a combined measure of glutamine and glutamate) in the medial temporal lobe. 17 The few 1 H-MRS studies that examined hippocampal glutamate concentrations in clinical high-risk individuals did not find differences compared with healthy control individuals, 18-20 but they did not investigate hippocampal glutamate concentrations in association with clinical outcomes. Associations between glutamate levels and adverse outcomes in clinical high-risk individuals have been identified in 1 H-MRS studies of other brain regions. de la Fuente Sandoval et al 21 found that glutamate levels in the striatum were elevated in clinical high-risk individuals who developed psychosis subsequent to scanning but not in clinical high-risk individuals who did not. Furthermore, in the thalamus, low baseline glutamate levels were associated with poor functioning at clinical follow-up 22 and with a failure to achieve symptomatic remission from the clinical high-risk state.
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The primary aim of the present study was to investigate the association between hippocampal glutamate levels in clinical high-risk individuals and subsequent clinical outcomes. We used 1 H-MRS to examine a sample of clinical high-risk individuals and a group of healthy volunteers. Clinical high-risk individuals were followed up to determine their clinical outcomes, which were assessed in terms of transition or nontransition to psychosis and level of overall functioning. Our primary hypothesis was that in clinical high-risk individuals, elevated hippocampal glutamate levels at baseline would be associated with the following adverse clinical outcomes: the onset of psychosis and a low level of overall functioning. In view of the evidence of a more general disruption of hippocampal function before the onset of psychosis, we also explored the association between clinical outcomes and levels of other hippocampal metabolites.
Methods

Participants
A total of 116 individuals participated in the study, including 86 individuals at high risk and 30 healthy controls. The study protocol was approved by the National Research Ethics Service Committee of London-Camberwell St Giles, United Kingdom, and all participants gave written informed consent. The study was conducted between November 1, 2011, and November 1, 2017. The 86 clinical high-risk individuals were recruited in the United Kingdom through the following early detection services for people at clinical high risk for psychosis: Outreach and Support in South London, the West London Early Intervention service, and the Cambridge Early Onset service. 24 The diagnosis was made using the Comprehensive Assessment of the At-Risk Mental State. 25 Individuals met 1 or more of the following criteria: (1) attenuated psychotic symptoms; (2) brief, limited intermittent psychotic symptoms (a history of 1 or more episodes of frank psychotic symptoms that resolved spontaneously within 1 week in the past year); or (3) a recent decline in function, together with either the presence of schizotypal personality disorder or a family history of psychosis in a first-degree relative. Thirty healthy controls were recruited from the local community. All were native English speakers and had no history of psychiatric disorder. None of the healthy controls was using prescription medication.
On the day of scanning, symptoms of clinical high-risk patients were assessed using the Comprehensive Assessment of the At-Risk Mental State. 26 For all participants, psychosocial functioning was examined using the Global Assessment of Function (GAF) scale, 26 measures of anxiety were obtained using the Hamilton Anxiety Rating Scale, and measures of depression were obtained using the Hamilton Depression Rating Scale. 
Clinical Follow-up
The clinical high-risk individual sample was followed up to determine clinical outcomes. Fifty-seven individuals underwent a face-to-face clinical reassessment. The mean (SD) interval between the baseline and follow-up assessments was 18.5 (9.6) months (range, 4-59 months). Clinical outcome was assessed as transition or nontransition to psychosis, defined using the criteria in the Comprehensive Assessment of the At-Risk Mental State, 25 and the level of overall functioning determined using the GAF scale. Of the 86 clinical high-risk individuals, 29 (34%) could not be interviewed again because they were too unwell, declined to be seen, or were unable to be contacted. For these individuals, the transition to psychosis was determined from information in their clinical records, but it was not possible to rate their overall functioning.
Proton Magnetic Resonance Spectroscopy
Images were obtained on a 3.0T HDx MR system (General Electric Healthcare). The 1 H-MRS spectra (Point RESolved Spectroscopy; 30-millisecond echo time; 3000-millisecond repetition time; 96 averages) were acquired in the left hippocampus ( Figure 1) . 19 We used the standard General Electric probe (proton brain examination) sequence, which uses a standardized, chemically selective suppression, water suppression routine. For each metabolite spectrum, unsuppressed water reference spectra (16 averages) were also part of the standard acquisition. Shimming and water suppression were optimized, with auto-prescan performed twice before each scan. 
Statistical Analysis
Group differences in clinical and demographic variables were assessed using 2-sample t tests or χ 2 tests. To examine the association between metabolite levels and clinical outcomes, the clinical high-risk sample was dichotomized according to transition vs nontransition to psychosis 25 and good overall functioning (GAF≥65) vs poor overall functioning (GAF<65) at follow-up. 22 Because the primary hypothesis involved the association between hippocampal glutamate levels and clinical outcomes, general linear models were used to identify group differences in glutamate levels between the respective clinical high-risk subgroups and healthy controls, as well as between the total clinical high-risk group and healthy controls. Glutamate concentrations were included as the dependent variable with group as the independent variable (2-tailed P < .05 was considered to be statistically significant). Concentrations of other metabolites (Glx, myo-inositol, creatine, choline, and N-acetylaspartate) were also assessed in exploratory general linear models and were corrected for multiple comparisons (thresholded P < .01). Multiple regression analyses were performed to examine how hippocampal glutamate levels were associated with clinical outcomes. Age and tobacco use were included as covariates in all analyses because both can influence neurometabolite levels. Table 1) .
At follow-up of 18.5 months, 12 clinical high-risk individuals (14%) developed a first episode of psychosis (transition group) and 74 (86%) did not (nontransition group). When dichotomized according to their GAF scores, 19 of the 57 clinical high-risk individuals who were reinterviewed (33%) showed good overall functioning (GAF≥65), whereas 38 of the 57 clinical high-risk individuals who were reinterviewed (67%) had a poor functional outcome (GAF<65).
The transition group had higher baseline Hamilton Anxi- 1] scores; P < .05) than did the nontransition group, but there were no other significant differences in symptom ratings or demographic measures between these subgroups. There were no significant differences at baseline in any clinical or demographic measures between the good outcome and poor outcome subgroups (Table 1) (eTables 4 and 5 in the Supplement).
Hippocampal Metabolite Differences
Results from logistic regression analyses showed that hippocampal glutamate levels were significantly associated with clinical outcome in terms of transition and nontransition to psychosis (β = 0.48; odds ratio = 1.61; 95% CI, 1.00-2.59; P = .05) and overall functioning (β = 0.53; odds ratio = 1.71; 95% CI, 1.10-2.66; P = .02). There were no significant group differences in any of the metabolite concentrations between the total clinical high-risk group (independent of outcomes) and healthy controls ( Table 2 and eFigures 1-3 in the Supplement).
Transition to Psychosis
The transition subgroup had significantly higher hippocampal glutamate levels than did the nontransition subgroup (mean [SD] F 3,38 = 3.54; P = .07) although the latter fell short of statistical significance. There was no difference in glutamate levels between the nontransition and healthy control groups ( Figure 2 and eFigure 1 and eTable 6 in the Supplement).
Exploratory testing revealed that the transition group also had significantly higher hippocampal myo-inositol levels than did the nontransition group (mean [SD] F 3,38 = 8.82; P = .005). The differences in myo-inositol levels were large; in the transition group, the concentration was 22% higher than in the nontransition group (Hedges g, 1.01) and 23% higher than in healthy controls (Hedges g,0.98).In contrast, there were no significant differences between nontransition individuals and healthy controls in the levels of any hippocampal metabolite (Figure 2 , eFigures 2 and 3, and eTable 6 in the Supplement).
Functional Outcome
Clinical high-risk individuals with a poor functional outcome had significantly higher glutamate levels than did those with a good outcome (mean [SD], 8.83 [1.43] vs 7.76 [1.40] ; Hedges g, 0.75; F 3,52 = 6.39; P = .02). There were no other significant differences in metabolite levels. None of the metabolite levels was significantly different between either of the clinical high-risk functional outcome subgroups and the healthy controls ( Figure 3 , eFigures 1-3, and eTable 7 in the Supplement). 
Discussion
To our knowledge, this was the largest 1 H-MRS study of metabolite levels in individuals at clinical high risk of psychosis conducted to date. The overall finding was that adverse clinical outcomes in these individuals were associated with increases in hippocampal glutamate levels and in the levels of some other metabolites. The subsequent onset of psychosis was associated with higher baseline levels of glutamate, myoinositol, and creatine at first clinical presentation, and a low level of functioning at follow-up was associated with increased glutamate levels. In contrast to the differences within the clinical high-risk group, there were no differences in metabolite levels between the total clinical high-risk sample and healthy controls or between clinical high-risk individuals who did not have adverse clinical outcomes and controls.
In line with our main hypothesis, increased hippocampal glutamate levels at baseline were associated with adverse clinical outcomes at follow-up, including onset of psychosis and a low level of overall functioning. These observations are consistent with preclinical and human data implicating hippocampal dysfunction and glutamate transmission in the development of psychosis. In preclinical models, neural hyperactivity of the hippocampus drives an increase in subcortical dopamine activity through glutamatergic projections to the striatum. that a poor functional outcome in clinical high-risk individuals was linked to lower glutamate concentrations in the thalamus at baseline, whereas Egerton et al 23 reported that lower thalamic glutamate levels were associated with a failure to achieve symptomatic remission from the clinical high-risk state. Our second main finding was that adverse clinical outcomes were also associated with elevations in the levels of myo-inositol and creatine in the hippocampus. For both these metabolites and for glutamate, the pattern of group differences was similar, with higher levels in clinical high-risk individuals who developed psychosis compared with those who did not become psychotic (Figure 2 , eFigures 1-3, and eTable 6intheSupplement). This consistent pattern across different metabolites suggests that the onset of psychosis was associated with a more general increase in hippocampal metabolite levels, as opposed to a change that was specific to glutamate. Such a widespread change in metabolites is consistent with previous evidence that the subsequent onset of psychosis in clinical high-risk individuals is associated with an overall change in hippocampal integrity, as indicated by hypermetabolism, In the present study, the elevation in myo-inositol levels was large, with concentrations around 22% higher (and effect sizes approximately 1.0) in the clinical high-risk individuals who developed psychosis than in both clinical high-risk individuals who did not develop psychosis and healthy controls. Myo-inositol is regarded as a marker for glial activation, 38 and independent data from positron emission tomographic studies of glial activity have reported that this is increased in the hippocampus (and in other regions) in clinical high-risk individuals and those with psychosis. H-MRS values were corrected for cerebrospinal fluid volume, we cannot exclude the possibility that increased metabolite concentrations were associated with changes in hippocampal volume. Finally, by using conventional 1 H-MRS, it is not possible to determine whether differences in glutamate levels are associated with neurotransmission or metabolism, an issue that may be addressed by using more sophisticated MRS protocols.
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Conclusions
Our study suggests that clinical outcomes in patients at clinical high risk for psychosis may be associated with baseline hippocampal metabolite concentrations. Although the findings require replication, they raise the possibility that measuring hippocampal metabolite levels could contribute to the stratification of clinical high-risk individuals according to future clinical outcomes. 
